×
  • Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Hepatitis C Diagnosis Treatment Market Size

    ID: MRFR/MED/1040-HCR
    90 Pages
    Kinjoll Dey
    October 2025

    Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Hepatitis C Diagnosis Treatment Market Infographic
    Purchase Options

    Hepatitis C Diagnosis Treatment Size

    Hepatitis C Diagnosis Treatment Market Growth Projections and Opportunities

    The size of the Hepatitis C diagnosis and treatment market is projected to be USD 80.63 billion by 2030 with a CAGR of 12.4% during the forecast period. The landscape and growth trajectory of the Hepatitis C diagnosis and treatment market are influenced by several market factors. One of the major drivers in this market is the global prevalence of Hepatitis C which is high. This disease is a significant challenge to public health since it has affected millions of people leading to a high demand for effective diagnostic solutions and treatments. Hence, as awareness about HCV increases, and screening intensifies, there will be steady growth in the diagnostics and treatment market

    Technology developments determine the functioning of the Hepatitis C Diagnosis and Treatment market. Advances in diagnostic tools, as well as therapeutic options, have improved detection methods for virus presence as well as disease management. Through early detection, advanced diagnostics such as nucleic acid testing and serological assays offer opportunities for timely intervention. Similarly, direct-acting antiviral drugs development has changed HCV therapy significantly offering higher cure rates within shorter durations.

    Regulatory concerns are some key drivers influencing the hepatitis c market dynamics. Regulatory approvals for diagnostic tests, as well as treatment regimens, are stringent due to potential public health impact that may result from them. In conformity with regulatory standards ensures products’ safety plus efficacy thereby giving confidence to medical practitioners alongside patients who use them. With approved products having wider acceptance hence gaining a lot of credibility in the markets than ever before; this therefore shows how regulatory pathway acts shaping competitive landscape.

    Public awareness and acceptance are two key factors affecting hepatitis c dynamics within the market. Raising awareness about importance of early diagnosis, availability of effective treatments along with consequences associated with untreated Hepatitis C is necessary. Market has been positively impacted through public health campaigns alongside education efforts which have resulted to an increase in screening rates as well as treatment seeking behavior.

    Hepatitis C Diagnosis Treatment Market Size Graph
    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is the current valuation of the Hepatitis C Diagnosis and Treatment Market?

    The market valuation was 46.55 USD Billion in 2024.

    What is the projected market size for the Hepatitis C Diagnosis and Treatment Market by 2035?

    The market is projected to reach 117.48 USD Billion by 2035.

    What is the expected CAGR for the Hepatitis C Diagnosis and Treatment Market during the forecast period?

    The expected CAGR for the market from 2025 to 2035 is 8.78%.

    Which companies are the key players in the Hepatitis C Diagnosis and Treatment Market?

    Key players include Gilead Sciences, AbbVie, Merck & Co, and Bristol-Myers Squibb.

    What are the main segments of the Hepatitis C Diagnosis market?

    The main segments include Liver Function Tests, Liver Biopsy, Blood Tests, and Others.

    Market Summary

    As per MRFR analysis, the Hepatitis C Diagnosis and Treatment Market was estimated at 46.55 USD Billion in 2024. The Hepatitis C industry is projected to grow from 50.64 USD Billion in 2025 to 117.48 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.78 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Hepatitis C Diagnosis and Treatment Market is experiencing transformative advancements driven by technology and rising disease prevalence.

    • Advancements in diagnostic technologies are enhancing the accuracy and speed of Hepatitis C detection, particularly in North America.
    • The emergence of novel antiviral therapies is reshaping treatment protocols, with a notable focus on personalized medicine in the Asia-Pacific region.
    • Integration of telemedicine is facilitating patient care and follow-up, especially in remote areas, thereby improving access to treatment.
    • Rising prevalence of Hepatitis C and increased government initiatives and funding are driving market growth across both diagnostic and treatment segments.

    Market Size & Forecast

    2024 Market Size 46.55 (USD Billion)
    2035 Market Size 117.48 (USD Billion)
    CAGR (2025 - 2035) 8.78%
    Largest Regional Market Share in 2024 Americas

    Major Players

    <p>Gilead Sciences (US), AbbVie (US), Merck & Co (US), Bristol-Myers Squibb (US), Roche (CH), Johnson & Johnson (US), GlaxoSmithKline (GB), Hoffmann-La Roche (CH), AstraZeneca (GB)</p>

    Market Trends

    The Hepatitis C Diagnosis and Treatment Market is currently experiencing a transformative phase, driven by advancements in medical technology and a growing awareness of the disease's impact on public health. Innovative diagnostic tools are emerging, enhancing the accuracy and speed of Hepatitis C detection. This evolution is complemented by the development of new antiviral therapies, which are showing promise in improving patient outcomes. As healthcare systems worldwide prioritize the elimination of Hepatitis C, there is a noticeable shift towards integrated care models that encompass prevention, diagnosis, and treatment. This holistic approach appears to foster better patient engagement and adherence to treatment protocols. Moreover, the landscape of the Hepatitis C Diagnosis and Treatment Market is influenced by increasing collaborations between pharmaceutical companies and healthcare providers. These partnerships aim to streamline access to therapies and improve the overall management of the disease. Additionally, the rise of telemedicine is reshaping how patients interact with healthcare professionals, potentially increasing the reach of diagnostic services and treatment options. As the market evolves, it seems poised to address the challenges of Hepatitis C more effectively, ultimately contributing to the global goal of reducing the burden of this viral infection.

    Advancements in Diagnostic Technologies

    The Hepatitis C Diagnosis and Treatment Market is witnessing a surge in innovative diagnostic technologies. These advancements are enhancing the precision and efficiency of Hepatitis C detection, allowing for earlier intervention and improved patient management. New methods, such as point-of-care testing, are becoming increasingly prevalent, facilitating rapid diagnosis in diverse healthcare settings.

    Emergence of Novel Antiviral Therapies

    The development of novel antiviral therapies is reshaping treatment paradigms within the Hepatitis C Diagnosis and Treatment Market. These new medications are designed to be more effective and have fewer side effects, potentially leading to higher rates of patient compliance. This trend indicates a shift towards personalized treatment approaches that cater to individual patient needs.

    Integration of Telemedicine in Patient Care

    The integration of telemedicine into the Hepatitis C Diagnosis and Treatment Market is transforming patient care dynamics. This approach allows for remote consultations and monitoring, which can enhance access to healthcare services, particularly in underserved areas. Telemedicine may also facilitate ongoing patient education and support, contributing to better health outcomes.

    Hepatitis C Diagnosis Treatment Market Market Drivers

    Rising Prevalence of Hepatitis C

    The increasing prevalence of Hepatitis C infections is a primary driver for the Hepatitis C Diagnosis and Treatment Market. According to estimates, millions of individuals are living with chronic Hepatitis C worldwide, with a notable rise in cases reported in certain regions. This surge in prevalence necessitates enhanced diagnostic and treatment solutions, thereby propelling market growth. The World Health Organization has indicated that Hepatitis C is a significant public health concern, leading to liver disease and other complications. As awareness of the disease grows, healthcare systems are compelled to invest in advanced diagnostic technologies and effective treatment options, further stimulating the Hepatitis C Diagnosis and Treatment Market.

    Increased Awareness and Education

    The growing awareness and education surrounding Hepatitis C are pivotal for the Hepatitis C Diagnosis and Treatment Market. Public health campaigns and educational programs have played a significant role in informing individuals about the risks and consequences of Hepatitis C. This heightened awareness encourages individuals to seek testing and treatment, thereby increasing the demand for diagnostic services and therapeutic interventions. Healthcare providers are also becoming more knowledgeable about the disease, leading to improved patient management and care. As awareness continues to rise, the Hepatitis C Diagnosis and Treatment Market is expected to expand, driven by the need for comprehensive care and support for affected individuals.

    Government Initiatives and Funding

    Government initiatives aimed at combating Hepatitis C are crucial for the Hepatitis C Diagnosis and Treatment Market. Various countries have implemented national strategies to eliminate Hepatitis C, which include funding for screening programs and treatment accessibility. For instance, some governments have allocated substantial budgets to enhance public health campaigns and improve healthcare infrastructure. These initiatives not only raise awareness but also facilitate early diagnosis and treatment, which are essential for controlling the disease's spread. The financial support from governments encourages research and development in the Hepatitis C Diagnosis and Treatment Market, leading to innovative solutions and improved patient outcomes.

    Integration of Personalized Medicine

    The integration of personalized medicine into Hepatitis C treatment strategies is emerging as a key driver for the Hepatitis C Diagnosis and Treatment Market. Tailoring treatment plans based on individual patient profiles, including genetic factors and disease progression, enhances treatment efficacy and minimizes adverse effects. This approach not only improves patient outcomes but also fosters a more efficient allocation of healthcare resources. As healthcare systems increasingly adopt personalized medicine, the demand for diagnostic tools that can accurately assess patient-specific factors is likely to grow. Consequently, the Hepatitis C Diagnosis and Treatment Market may witness a shift towards more individualized treatment paradigms, reflecting the evolving landscape of healthcare.

    Technological Innovations in Treatment

    Technological advancements in treatment options are significantly influencing the Hepatitis C Diagnosis and Treatment Market. The introduction of direct-acting antiviral agents has revolutionized the treatment landscape, offering higher cure rates and shorter treatment durations. These innovations have made Hepatitis C treatment more effective and accessible, attracting a larger patient population. Furthermore, ongoing research into new therapeutic agents continues to expand the treatment arsenal, which is expected to enhance patient compliance and outcomes. As healthcare providers adopt these advanced therapies, the Hepatitis C Diagnosis and Treatment Market is likely to experience substantial growth, driven by the demand for effective and efficient treatment solutions.

    Market Segment Insights

    By Diagnosis: Blood Tests (Largest) vs. Liver Biopsy (Fastest-Growing)

    <p>Within the Hepatitis C Diagnosis and Treatment Market, Blood Tests dominate the segment, accounting for the largest share among diagnostic tools. They are widely used due to their effectiveness in detecting the Hepatitis C virus (HCV) and are considered a standard practice in the diagnostic process. In comparison, Liver Biopsy, although smaller in market share, is emerging rapidly due to the increasing emphasis on accurate liver assessment and damage evaluation, contributing significantly to its growth potential in the market.</p>

    <p>Blood Tests (Dominant) vs. Liver Biopsy (Emerging)</p>

    <p>Blood Tests hold a dominant position in the Hepatitis C diagnosis landscape as they are essential for initial screening and follow-up to confirm HCV infection. Their non-invasive nature and efficiency make them the preferred choice among healthcare providers. Conversely, Liver Biopsy, while invasive, is gaining traction as an emerging technique, particularly for detailed liver damage assessment. This method offers critical insights into the stage of liver disease, often supporting treatment decisions. Increasing awareness about liver health and ongoing advancements in biopsy techniques are driving its growth, positioning it as a vital tool for comprehensive Hepatitis C management.</p>

    By Treatment: Antiviral Medications (Largest) vs. Immune-Modulators (Fastest-Growing)

    <p>In the Hepatitis C Diagnosis and Treatment Market, the primary contributors stand out, highlighting the dynamics of market share distribution. Antiviral medications dominate the landscape, claiming a significant portion. In contrast, immune-modulators, while currently a smaller market player, are rapidly gaining traction among healthcare providers, reflecting a shift towards a more holistic treatment philosophy.</p>

    <p>Antiviral Medications (Dominant) vs. Immune-Modulators (Emerging)</p>

    <p>Antiviral medications serve as the cornerstone in the treatment of Hepatitis C, renowned for their efficacy in eradicating the virus and leading to sustained virological response in patients. These therapies, including direct-acting antivirals (DAAs), have transformed patient outcomes. On the other hand, immune-modulators represent a burgeoning area in treatment innovation. Although still developing, they are showing promise in enhancing the body's immune response against the virus, positioning them as an attractive option for future therapies. As research continues to progress, the potential of immune-modulators could revolutionize treatment paradigms further.</p>

    By End User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

    <p>In the Hepatitis C Diagnosis and Treatment Market, hospitals and clinics command the largest market share due to their comprehensive healthcare services and access to advanced diagnostic technologies. These facilities cater to a significant patient demographic, thereby playing a crucial role in the management of hepatitis C treatment protocols. Conversely, diagnostic centers, while holding a smaller market share, are rapidly gaining ground as more patients seek specialized services that these facilities provide. This shift emphasizes the growing reliance on precision diagnostics and targeted treatment plans.</p>

    <p>Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)</p>

    <p>Hospitals and clinics remain the dominant segment in the Hepatitis C Diagnosis and Treatment Market, offering a wide range of services that encompass the entire spectrum of patient management, from diagnosis to treatment and follow-up care. Their established infrastructure and skilled healthcare professionals enable them to deliver high-quality care, making them the first point of contact for most patients. On the other hand, diagnostic centers are emerging as vital players in this landscape. With a growing emphasis on rapid and accurate diagnostics, these centers focus on specialized services tailored to hepatitis C, appealing to both physicians and patients seeking more efficient healthcare solutions. As technological advancements continue to enhance diagnostic capabilities, the growth prospects for this segment are notably robust.</p>

    Get more detailed insights about Hepatitis C Diagnosis and Treatment Market Research Report - Forecast till 2035

    Regional Insights

    Key Companies in the Hepatitis C Diagnosis Treatment Market market include

    Industry Developments

    In India, Abbott introduced "LiverHealth," a project to make it easier to diagnose liver function and promote awareness about hepatitis C.

    The market is consolidated, with Gilead Sciences, Inc. accounting for roughly 80.1 percent of the market share, with the majority of revenue coming from the sales of the medications Harvoni and Sovaldi. Bristol-Myers Squibb Company and AbbVie Inc. are the other main participants.

    Future Outlook

    Hepatitis C Diagnosis Treatment Market Future Outlook

    <p>The Hepatitis C Diagnosis and Treatment Market is projected to grow at an 8.78% CAGR from 2024 to 2035, driven by advancements in diagnostics, increased awareness, and improved treatment options.</p>

    New opportunities lie in:

    • <p>Development of point-of-care testing devices for rapid diagnosis.</p>
    • <p>Expansion of telemedicine services for remote patient management.</p>
    • <p>Investment in personalized medicine approaches for tailored treatment regimens.</p>

    <p>By 2035, the market is expected to be robust, driven by innovation and increased accessibility.</p>

    Market Segmentation

    Hepatitis C Diagnosis Treatment Market End User Outlook

    • Hospitals & Clinics
    • Diagnostic Centers
    • Others

    Hepatitis C Diagnosis Treatment Market Diagnosis Outlook

    • Liver Function Tests
    • Liver Biopsy
    • Blood Tests
    • Others

    Hepatitis C Diagnosis Treatment Market Treatment Outlook

    • Antiviral Medications
    • Immune-Modulators
    • Liver Transplantation
    • Others

    Report Scope

    MARKET SIZE 202446.55(USD Billion)
    MARKET SIZE 202550.64(USD Billion)
    MARKET SIZE 2035117.48(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)8.78% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in direct-acting antiviral therapies enhance treatment efficacy in the Hepatitis C Diagnosis and Treatment Market.
    Key Market DynamicsRising demand for innovative therapies drives competition and regulatory scrutiny in the Hepatitis C diagnosis and treatment market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the current valuation of the Hepatitis C Diagnosis and Treatment Market?

    The market valuation was 46.55 USD Billion in 2024.

    What is the projected market size for the Hepatitis C Diagnosis and Treatment Market by 2035?

    The market is projected to reach 117.48 USD Billion by 2035.

    What is the expected CAGR for the Hepatitis C Diagnosis and Treatment Market during the forecast period?

    The expected CAGR for the market from 2025 to 2035 is 8.78%.

    Which companies are the key players in the Hepatitis C Diagnosis and Treatment Market?

    Key players include Gilead Sciences, AbbVie, Merck & Co, and Bristol-Myers Squibb.

    What are the main segments of the Hepatitis C Diagnosis market?

    The main segments include Liver Function Tests, Liver Biopsy, Blood Tests, and Others.

    1. MARKET INTRODUCTION
      1. Definition
      2. Scope
        1. Assumptions
        2. Limitations
      3. of the Study
      4. 2.2.1.
      5. Research Objective
      6. RESEARCH
      7. METHODOLOGY
      8. Overview
      9. Primary Research
      10. Secondary
      11. Research
      12. 3.4.
      13. Market Size Estimation
    2. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
      5. MARKET
    3. FACTOR ANALYSIS
      1. Porter’s Five Forces Analysis
        1. Bargaining
        2. Bargaining Power of Buyers
        3. Threat
        4. Intensity of Rivalry
      2. Power of Suppliers
      3. of New Entrants
      4. 5.1.4.
      5. Threat of Substitutes
      6. Value
      7. Chain Analysis
      8. GLOBAL
    4. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS
      1. Overview
      2. Liver
      3. Function Tests
      4. Market
      5. Estimates & Forecast, by Region, 2020-2027
    5. Market Estimates & Forecast, by Country, 2020-2027
      1. Liver
      2. Biopsy
      3. Market
      4. Estimates & Forecast, by Region, 2020-2027
    6. Market Estimates & Forecast, by Country, 2020-2027
      1. Blood
      2. Tests
      3. Market
      4. Estimates & Forecast, by Region, 2020-2027
    7. Market Estimates & Forecast, by Country, 2020-2027
      1. Others
      2. Market Estimates & Forecast,
      3. by Region, 2020-2027
    8. Market Estimates & Forecast, by Country, 2020-2027
      1. GLOBAL
    9. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT
      1. Overview
      2. Antiviral
      3. Medications
      4. Market
      5. Estimates & Forecast, by Region, 2020-2027
    10. Market Estimates & Forecast, by Country, 2020-2027
      1. Immuno-Modulators
      2. Market Estimates & Forecast,
      3. by Region, 2020-2027
    11. Market Estimates & Forecast, by Country, 2020-2027
      1. Liver
      2. Transplantation
      3. Market
      4. Estimates & Forecast, by Region, 2020-2027
    12. Market Estimates & Forecast, by Country, 2020-2027
      1. Others
      2. Market Estimates & Forecast,
      3. by Region, 2020-2027
    13. Market Estimates & Forecast, by Country, 2020-2027
      1. GLOBAL
    14. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER
      1. Overview
      2. Hospitals
      3. and Clinics
      4. Market
      5. Estimates & Forecast, by Region, 2020-2027
    15. Market Estimates & Forecast, by Country, 2020-2027
      1. Diagnostic
      2. Centers
      3. Market
      4. Estimates & Forecast, by Region, 2020-2027
    16. Market Estimates & Forecast, by Country, 2020-2027
      1. Others
      2. Market Estimates & Forecast,
      3. by Region, 2020-2027
    17. Market Estimates & Forecast, by Country, 2020-2027
      1. GLOBAL
    18. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION
      1. Overview
      2. Americas
        1. North
        2. Eastern Europe
      3. America
      4. 9.2.1.1.
      5. US
      6. 9.2.1.2.
      7. Canada
      8. 9.2.2.
      9. Latin America
      10. 9.3.
      11. Europe
      12. 9.3.1.
      13. Western Europe
      14. 9.3.1.1.
      15. Germany
      16. 9.3.1.2.
      17. France
      18. 9.3.1.3.
      19. Italy
      20. 9.3.1.4.
      21. Spain
      22. 9.3.1.5.
      23. UK
      24. 9.3.1.6.
      25. Rest of Western Europe
      26. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South
      27. Korea
      28. 9.4.6.
      29. Rest of Asia-Pacific
      30. Middle East & Africa
        1. Middle
      31. East
      32. 9.5.2.
      33. Africa
    19. COMPANY LANDSCAPE
      1. Overview
      2. Competitive
      3. Analysis
      4. 10.3.
      5. Market Share Analysis
      6. Major Growth Strategy in the Global Hepatitis
      7. C Diagnosis and Treatment Market
      8. Competitive Benchmarking
      9. Leading
      10. Players in Terms of the Number of Developments in the Global Hepatitis C Diagnosis
      11. and Treatment Market
      12. Key Developments and Growth Strategies
        1. Product
        2. Mergers and Acquisitions
        3. Joint
        4. Sales & Operating
      13. Launch/Service Deployment
      14. Ventures
      15. 10.8.
      16. Major Players Financial Matrix & Market Ratio
      17. Income 2020
      18. 10.8.2.
      19. Major Players R&D Expenditure 2020
      20. Major Players Capital Market
      21. Ratio
      22. COMPANY PROFILES
      23. F. Hoffmann-La Roche Ltd
        1. Company
        2. Product Overview
        3. Financial
        4. SWOT Analysis
        5. Key
        6. Company Overview
        7. Product
        8. Financial Overview
        9. Key
        10. SWOT Analysis
        11. Key
        12. Company Overview
        13. Product
        14. Financial Overview
        15. Key
        16. SWOT Analysis
        17. Key
        18. Financial Overview
        19. Key
        20. SWOT Analysis
        21. Key
        22. Company Overview
        23. Product
        24. Financial Overview
        25. Key
        26. SWOT Analysis
        27. Key
        28. Company Overview
        29. Product
        30. Financial Overview
        31. Key
        32. SWOT Analysis
        33. Key
        34. Company Overview
        35. Product
        36. Financial Overview
        37. Key
        38. SWOT Analysis
        39. Key
        40. Financial Overview
        41. Key
        42. SWOT Analysis
        43. Key
        44. Company Overview
        45. Product
        46. Financial Overview
        47. Key
        48. SWOT Analysis
        49. Key
        50. Company Overview
        51. Financial Overview
        52. SWOT Analysis
        53. Financial Overview
        54. SWOT Analysis
        55. Financial Overview
        56. SWOT Analysis
        57. Financial Overview
        58. SWOT Analysis
        59. Company Overview
        60. Financial Overview
        61. SWOT Analysis
        62. Financial Overview
        63. SWOT Analysis
        64. Company Overview
        65. Financial Overview
        66. SWOT Analysis
      24. Overview
      25. Overview
      26. 11.1.4.
      27. Key Developments
      28. Strategies
      29. 11.2.
      30. Vertex Pharmaceuticals Incorporated
      31. Overview
      32. Developments
      33. Strategies
      34. 11.3.
      35. Gilead Sciences, Inc.
      36. Overview
      37. Developments
      38. Strategies
      39. 11.4.
      40. AbbVie Inc.
      41. 11.4.1.
      42. Company Overview
      43. 11.4.2.
      44. Product Overview
      45. Developments
      46. Strategies
      47. 11.5.
      48. GlaxoSmithKline plc
      49. Overview
      50. Developments
      51. Strategies
      52. 11.6.
      53. Novartis Pharmaceuticals Corporation
      54. Overview
      55. Developments
      56. Strategies
      57. 11.7.
      58. Bristol-Myers Squibb Company
      59. Overview
      60. Developments
      61. Strategies
      62. 11.8.
      63. Abbott.
      64. 11.8.1.
      65. Company Overview
      66. 11.8.2.
      67. Product Overview
      68. Developments
      69. Strategies
      70. 11.9.
      71. Beckman Coulter, Inc.
      72. Overview
      73. Developments
      74. Strategies
      75. 11.10.
      76. Siemens Medical Solutions USA, Inc.
      77. 11.10.2.
      78. Product Overview
      79. 11.10.4.
      80. Key Developments
      81. 11.10.6.
      82. Key Strategies
      83. 11.11.
      84. MedMira Inc.
      85. 11.11.1.
      86. Company Overview
      87. 11.11.2.
      88. Product Overview
      89. 11.11.4.
      90. Key Developments
      91. 11.11.6.
      92. Key Strategies
      93. 11.12.
      94. DiaSorin SpA
      95. 11.12.1.
      96. Company Overview
      97. 11.12.2.
      98. Product Overview
      99. 11.12.4.
      100. Key Developments
      101. 11.12.6.
      102. Key Strategies
      103. 11.13.
      104. Qiagen
      105. 11.13.1.
      106. Company Overview
      107. 11.13.2.
      108. Product Overview
      109. 11.13.4.
      110. Key Developments
      111. 11.13.6.
      112. Key Strategies
      113. 11.14.
      114. bioMérieux SA
      115. 11.14.2.
      116. Product Overview
      117. 11.14.4.
      118. Key Developments
      119. 11.14.6.
      120. Key Strategies
      121. 11.15.
      122. Hologic, Inc.
      123. 11.15.1.
      124. Company Overview
      125. 11.15.2.
      126. Product Overview
      127. 11.15.4.
      128. Key Developments
      129. 11.15.6.
      130. Key Strategies
      131. 11.16.
      132. Bio-Rad Laboratories, Inc.
      133. 11.16.2.
      134. Product Overview
      135. 11.16.4.
      136. Key Developments
      137. 11.16.6.
      138. Key Strategies
      139. 11.17.
      140. Others
      141. APPENDIX
      142. References
      143. Related
      144. Reports
    20. LIST OF TABLES
    21. GLOBAL
      1. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SYNOPSIS, 2020-2027
    22. GLOBAL
      1. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD
      2. MILLION)
    23. GLOBAL HEPATITIS C DIAGNOSIS
    24. AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
    25. GLOBAL
    26. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
    27. GLOBAL
    28. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
    29. GLOBAL
    30. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    31. NORTH
    32. AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD
      1. MILLION)
    33. NORTH
    34. AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD
      1. MILLION)
    35. NORTH
    36. AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD
      1. MILLION)
      2. TABLE 10
    37. US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
      1. TABLE 11
    38. US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
      1. TABLE 12
    39. US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)
    40. CANADA:
    41. HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)
      1. TABLE 14
    42. CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD
      1. MILLION)
      2. TABLE 15
    43. CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD
      1. MILLION)
      2. TABLE 16
    44. LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027
      1. (USD MILLION)
    45. LATIN AMERICA: HEPATITIS C DIAGNOSIS AND
    46. TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
      1. TABLE 18
    47. LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027
      1. (USD MILLION)
      2. TABLE
    48. EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS,
    49. EUROPE: HEPATITIS C DIAGNOSIS
    50. AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
      1. TABLE 21
    51. EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD
      1. MILLION)
      2. TABLE 22
    52. WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027
      1. (USD MILLION)
    53. WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND
    54. TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
      1. TABLE 24
    55. WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027
      1. (USD MILLION)
      2. TABLE 25
    56. EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027
      1. (USD MILLION)
      2. TABLE
    57. EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET,
      1. BY TREATMENT, 2020-2027 (USD MILLION)
      2. TABLE 27
    58. EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027
      1. (USD MILLION)
      2. TABLE 28
    59. ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027
      1. (USD MILLION)
    60. ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND
    61. TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)
      1. TABLE 30
    62. ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027
      1. (USD MILLION)
      2. TABLE 31
    63. MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS,
      1. TABLE 32
    64. MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT,
      1. TABLE 33
    65. MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER,
      1. LIST
    66. OF FIGURES
      1. FIGURE
    67. RESEARCH PROCESS
    68. MARKET STRUCTURE FOR
    69. THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET
      1. FIGURE 3
    70. MARKET DYNAMICS FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET
      1. FIGURE 4
    71. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY DIAGNOSIS, 2020
      1. (%)
      2. FIGURE
    72. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY
      1. TREATMENT TYPE, 2020 (%)
    73. GLOBAL HEPATITIS C DIAGNOSIS
    74. AND TREATMENT MARKET SHARE, BY END USER, 2020 (%)
      1. FIGURE 7
    75. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)
      1. FIGURE 7
      2. AMERICAS: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2020
      3. (%)
      4. FIGURE
    76. NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE,
      1. BY COUNTRY, 2020 (%)
    77. EUROPE: HEPATITIS C DIAGNOSIS
    78. AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)
    79. WESTERN EUROPE: HEPATITIS
    80. C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)
      1. FIGURE 11
    81. ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020
      1. (%)
      2. FIGURE
    82. MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT
    83. MARKET SHARE, BY COUNTRY, 2020 (%)
      1. FIGURE 13
      2. GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020
      3. (%)
      4. FIGURE
    84. F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
      1. FIGURE 15
      2. F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
    85. F. HOFFMANN-LA ROCHE
      1. LTD: REGIONAL REVENUE
    86. VERTEX PHARMACEUTICALS INCORPORATED: KEY
      1. FINANCIALS
      2. FIGURE
    87. VERTEX PHARMACEUTICALS INCORPORATED: SEGMENTAL REVENUE
      1. FIGURE 19
      2. VERTEX PHARMACEUTICALS INCORPORATED: REGIONAL REVENUE
    88. GILEAD SCIENCES, INC.:
      1. KEY FINANCIALS
      2. FIGURE
    89. GILEAD SCIENCES, INC.: SEGMENTAL REVENUE
      1. FIGURE 22
      2. GILEAD SCIENCES, INC.: REGIONAL REVENUE
    90. ABBVIE INC.: KEY FINANCIALS
      1. FIGURE 24
      2. ABBVIE INC.: SEGMENTAL REVENUE
    91. ABBVIE INC.: REGIONAL REVENUE
      1. FIGURE 26
      2. GLAXOSMITHKLINE PLC: KEY FINANCIALS
    92. GLAXOSMITHKLINE PLC:
      1. SEGMENTAL REVENUE
    93. GLAXOSMITHKLINE PLC: REGIONAL REVENUE
      1. FIGURE 29
      2. NOVARTIS PHARMACEUTICALS CORPORATION: KEY FINANCIALS
    94. NOVARTIS PHARMACEUTICALS
      1. CORPORATION: SEGMENTAL REVENUE
    95. NOVARTIS PHARMACEUTICALS CORPORATION:
      1. REGIONAL REVENUE
      2. FIGURE
    96. BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS
      1. FIGURE 33
      2. BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE
    97. BRISTOL-MYERS SQUIBB
      1. COMPANY: REGIONAL REVENUE
    98. ABBOTT.: KEY FINANCIALS
      1. FIGURE 36
      2. ABBOTT.: SEGMENTAL REVENUE
    99. ABBOTT.: REGIONAL REVENUE
      1. FIGURE 38
      2. BECKMAN COULTER, INC.: KEY FINANCIALS
    100. BECKMAN COULTER, INC.:
      1. SEGMENTAL REVENUE
    101. BECKMAN COULTER, INC.: REGIONAL REVENUE
      1. FIGURE 41
      2. SIEMENS MEDICAL SOLUTIONS USA, INC.: KEY FINANCIALS
    102. SIEMENS MEDICAL SOLUTIONS
      1. USA, INC.: SEGMENTAL REVENUE
    103. SIEMENS MEDICAL SOLUTIONS USA,
      1. INC.: REGIONAL REVENUE
    104. MEDMIRA INC.: KEY FINANCIALS
      1. FIGURE 45
      2. MEDMIRA INC.: SEGMENTAL REVENUE
    105. MEDMIRA INC.: REGIONAL REVENUE
      1. FIGURE 47
      2. DIASORIN S.P.A.: KEY FINANCIALS
    106. DIASORIN S.P.A.: SEGMENTAL
      1. REVENUE
      2. FIGURE
    107. DIASORIN S.P.A.: REGIONAL REVENUE
    108. QIAGEN: KEY FINANCIALS
      1. FIGURE 51
      2. QIAGEN: SEGMENTAL REVENUE
    109. QIAGEN: REGIONAL REVENUE
      1. FIGURE 53
      2. BIOMÉRIEUX SA: KEY FINANCIALS
    110. BIOMÉRIEUX SA:
      1. SEGMENTAL REVENUE
    111. BIOMÉRIEUX SA: REGIONAL REVENUE
      1. FIGURE 56
      2. HOLOGIC, INC.: KEY FINANCIALS
    112. HOLOGIC, INC.: SEGMENTAL REVENUE
      1. FIGURE 58
      2. HOLOGIC, INC.: REGIONAL REVENUE
    113. BIO-RAD LABORATORIES, INC.:
      1. KEY FINANCIALS
      2. FIGURE
    114. BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE
      1. FIGURE 61
      2. BIO-RAD LABORATORIES, INC.: REGIONAL REVENUE

    Hepatitis C Diagnosis and Treatment Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions